Rockley Photonics Holding Limited develops and supplies silicon photonics in the United Kingdom and internationally. It offers mobile platform for various solutions, such as photonic and electronic integrated circuits, sensing algorithms, artificial intelligence and cloud analytics, photonic and electronic co-packaging, firmware/software, and system architecture and hardware design that are used in health monitoring and machine vision for data communications. The company was founded in 2013 and is headquartered in England, the United Kingdom.
IPO Year:
Exchange: NYSE
Website: rockleyphotonics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2022 | $6.00 → $2.00 | Outperform → Neutral | Robert W. Baird |
| 3/9/2022 | $20.00 → $10.00 | Outperform | Northland Capital Markets |
| 3/9/2022 | $6.00 → $5.00 | Neutral | B of A Securities |
| 3/9/2022 | $15.00 → $8.00 | Buy | Needham |
| 12/22/2021 | $14.00 → $6.00 | Buy → Neutral | B of A Securities |
| 9/17/2021 | $14.00 | Buy | B of A Securities |
| 9/9/2021 | $22.00 | Outperform | Cowen |
| 9/7/2021 | $15.00 | Buy | Needham |
| 8/26/2021 | $18.00 | Outperform | Robert W. Baird |
Rockley Photonics Holdings Limited (NYSE:RKLY) ("Rockley"), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced that it received 12.9 million pounds sterling ($15.5 million) for its fiscal 2020 R&D tax credit from HMRC, the tax agency of the UK government. The Company filed its fiscal 2021 R&D tax credit application and expects to file its fiscal 2022 R&D tax credit application in 2023. About Rockley Photonics Formed in 2013, Rockley is a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions that target a portfo
Rockley Photonics Holdings Limited (NYSE:RKLY) ("Rockley"), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced that it received a notice from the New York Stock Exchange ("NYSE") on December 9, 2022, indicating that the Company is not in compliance with NYSE's continued listing standards, which require an average market capitalization of not less than $50 million over a 30 trading-day period and stockholders' equity of not less than $50 million. The notice has no immediate impact on the listing of Rockley's common stock on the NYSE, subject to the Company's compliance wit
Rickman to serve as executive chair; Becker promoted to interim chief financial officer Rockley Photonics Holdings Limited (NYSE:RKLY), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced changes to its senior management team. These changes are intended to position the Company for its next phase of growth. Effective immediately, Richard A. Meier has been appointed president and chief executive officer, and will join the board of directors. Dr. Andrew Rickman has resigned as chief executive officer and will take on the role of executive chairman of Rockley. Chad Becker wi
Rockley Photonics Holdings Limited (NYSE:RKLY), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced that Dr. Andrew Rickman, OBE, will join heads of government, senior ministers, and business leaders from across the Commonwealth to participate in the Commonwealth Trade and Investment Summit 2022. Dr. Rickman, chairman and CEO of Rockley Photonics, will participate in a panel entitled Global Pandemic Preparedness. He will join fellow session participants Dr. Tedros Adhanom Ghebreyesus, director-general, World Health Organisation, via pre-recorded video; Sir Patrick Vallanc
- Groundbreaking technology supports infrared and hyperspectral image detection and sensing devices to view images more clearly, at longer distances, and in low-light situations. - In collaboration with UC Santa Barbara, experiment shows first-time demonstration of a compact (micron-sized), monolithic silicon photonic electro-absorption-modulator maintaining its performance down to 4 Kelvin (-269.15 Celsius), enabling transmission of signals at cryogenically cooled temperatures with a compact, photonic integrated circuit. - Rockley's technology platform allows detection and sensing devices to be smaller in size and weight, and lower in power consumption. Rockley Photonics Holdings Limite
Rockley Photonics Holdings Limited (NYSE:RKLY), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced that it will participate in the following investor conferences. - Bernstein 2nd Annual CGM Disruptors Conference on Friday, November 18, 2022, at 11:05 a.m. ET - BTIG Digital Health Forum Panel on Monday, November 21, 2022, at 11:00 a.m. ET For access to the conferences, please contact your representatives at Bernstein and BTIG. When available, a live webcast and replay of the presentation will be accessible from the investor relations page of the Rockley Photonics Holdin
Additional capital raised through private placement Reduction in headcount and operating costs targets lower cash burn Advanced blood pressure biomarker by demonstrating promising intra-subject tracking against standard blood pressure cuff Rockley Photonics Holdings Limited (NYSE:RKLY), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced its financial results for the third quarter ended September 30, 2022. During the quarter, the Company advanced its technology platform, Bioptx™, through several technical and clinical targets: Expanded Free-Living Human Study of Its B
Rockley Photonics (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced that it plans to report its third quarter 2022 financial results after the market closes on Wednesday, November 9, 2022. The company also plans to host a conference call that day at 5:00 p.m. Eastern Time to review its financial results and business outlook. The conference call can be accessed by dialing 877-407-0832 from the United States or +1 201-689-8433 internationally, referencing Rockley Photonics. A live webcast and replay of the conference call can be accessed from the investor relations page on Rockley's website at investors.rockleyphotonics.com. Follo
Rockley to retain up to $24.5 million of incremental funding, of which $10.0 million will be received at closing Rockley Photonics Holdings Limited ("Rockley") (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced that it has entered into a definitive agreement with holders of outstanding Convertible Senior Secured Notes due 2026 (or their affiliates) and one new investor to issue approximately $90.6 million aggregate original principal amount of a new series of Convertible Senior Secured Notes due 2026 (the "New Notes") generating net proceeds after discount of approximately $89.4 million with an initial conversion price of $0.6888
Rockley Photonics Holdings Limited (NYSE:RKLY) ("Rockley"), a global leader in photonics-based health monitoring and communications solutions, today announced that it received a notice from the New York Stock Exchange ("NYSE") on October 18, 2022 indicating that the Company is not in compliance with NYSE's continued listing standards, which require common stock to maintain a minimum average closing price of $1.00 per share over a consecutive 30-day trading period. The notice has no immediate impact on the listing of Rockley's common stock on the NYSE, subject to the Company's compliance with the NYSE's other continued listing requirements, except that its ticker symbol will have an added de
Robert W. Baird downgraded Rockley Photonics from Outperform to Neutral and set a new price target of $2.00 from $6.00 previously
Northland Capital Markets reiterated coverage of Rockley Photonics Hldgs with a rating of Outperform and set a new price target of $10.00 from $20.00 previously
B of A Securities reiterated coverage of Rockley Photonics Hldgs with a rating of Neutral and set a new price target of $5.00 from $6.00 previously
Needham reiterated coverage of Rockley Photonics Hldgs with a rating of Buy and set a new price target of $8.00 from $15.00 previously
B of A Securities downgraded Rockley Photonics Hldgs from Buy to Neutral and set a new price target of $6.00 from $14.00 previously
B of A Securities initiated coverage of Rockley Photonics Hldgs with a rating of Buy and set a new price target of $14.00
Cowen initiated coverage of Rockley Photonics with a rating of Outperform and set a new price target of $22.00
Needham initiated coverage of Rockley Photonics Hldgs with a rating of Buy and set a new price target of $15.00
Robert W. Baird initiated coverage of Rockley Photonics with a rating of Outperform and set a new price target of $18.00
4 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
3 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
4 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
4 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
4 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
4 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
4 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
4 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
4 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
4 - Rockley Photonics Holdings Ltd (0001852117) (Issuer)
SC 13G/A - Rockley Photonics Holdings Ltd (0001852117) (Subject)
SC 13G - Rockley Photonics Holdings Ltd (0001852117) (Subject)
SC 13G - Rockley Photonics Holdings Ltd (0001852117) (Subject)
SC 13G/A - Rockley Photonics Holdings Ltd (0001852117) (Subject)
SC 13G/A - Rockley Photonics Holdings Ltd (0001852117) (Subject)
SC 13G - Rockley Photonics Holdings Ltd (0001852117) (Subject)
SC 13G - Rockley Photonics Holdings Ltd (0001852117) (Subject)
SC 13G - Rockley Photonics Holdings Ltd (0001852117) (Subject)
SC 13G/A - Rockley Photonics Holdings Ltd (0001852117) (Subject)
SC 13G - Rockley Photonics Holdings Ltd (0001852117) (Subject)
15-12G - Rockley Photonics Holdings Ltd (0001852117) (Filer)
10-K - Rockley Photonics Holdings Ltd (0001852117) (Filer)
8-K - Rockley Photonics Holdings Ltd (0001852117) (Filer)
NT 10-K - Rockley Photonics Holdings Ltd (0001852117) (Filer)
EFFECT - Rockley Photonics Holdings Ltd (0001852117) (Filer)
EFFECT - Rockley Photonics Holdings Ltd (0001852117) (Filer)
EFFECT - Rockley Photonics Holdings Ltd (0001852117) (Filer)
EFFECT - Rockley Photonics Holdings Ltd (0001852117) (Filer)
EFFECT - Rockley Photonics Holdings Ltd (0001852117) (Filer)
EFFECT - Rockley Photonics Holdings Ltd (0001852117) (Filer)
Additional capital raised through private placement Reduction in headcount and operating costs targets lower cash burn Advanced blood pressure biomarker by demonstrating promising intra-subject tracking against standard blood pressure cuff Rockley Photonics Holdings Limited (NYSE:RKLY), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced its financial results for the third quarter ended September 30, 2022. During the quarter, the Company advanced its technology platform, Bioptx™, through several technical and clinical targets: Expanded Free-Living Human Study of Its B
Rockley Photonics (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced that it plans to report its third quarter 2022 financial results after the market closes on Wednesday, November 9, 2022. The company also plans to host a conference call that day at 5:00 p.m. Eastern Time to review its financial results and business outlook. The conference call can be accessed by dialing 877-407-0832 from the United States or +1 201-689-8433 internationally, referencing Rockley Photonics. A live webcast and replay of the conference call can be accessed from the investor relations page on Rockley's website at investors.rockleyphotonics.com. Follo
Signs Supply Agreement and Receives First Commercial Purchase Order from Top-Tier Medtech Company for Bioptx™ Baseline Band, Targets Fourth Quarter to Begin Shipping Signs First Contract Research Organization Partnership to Develop and Evaluate Rockley's Bioptx™ Biomarker Sensing Platform for Use in Clinical Trials Bolsters Board of Directors and Establishes Scientific Advisory Board Rockley Photonics Holdings Limited (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced its financial results for the second quarter ended June 30, 2022. "I am proud of the progress we made in the second quarter. As we ramp towards commercial produc
Rockley Photonics (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced that it plans to report its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022. The company also plans to host a conference call that day at 5:00 p.m. Eastern Time to review its financial results and business outlook. The conference call can be accessed by dialing 866-682-6100 from the United States or +1 404-267-0373 internationally, referencing Rockley Photonics. A live webcast and replay of the conference call can be accessed from the investor relations page on Rockley's website at investors.rockleyphotonics.com. Follow
Collaboration Agreement Signed with Medtronic to Develop Next-Generation Wearable Healthcare Monitoring Devices, Utilizing Rockley's Bioptx™ Biomarker Sensing Platform VitalSpex™ Pro Biosensing Technology for Alcohol, Lactate, and Glucose Measurement Shipped to Tier-1 Customer Baseline Band Design Confirmed, Working with Contract Manufacturers to Support Fourth Quarter 2022 Production Timeline Rockley Photonics Holdings Limited (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced its financial results for the first quarter ended March 31, 2022. "We continue to make great progress on our biosensing platform, which we believe will
Rockley Photonics (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced that its first quarter 2022 financial results conference call has been rescheduled to after the market close on Thursday, May 12, 2022, to allow additional time to prepare its earnings report. The Company plans to host a conference call that day at 5:00 p.m. Eastern Time to review its financial results and business outlook. "By revising our earnings date, we expect to be able to share additional information on our earnings call that we are still reviewing; for example, the preliminary results from our human study on hydration and a new product shipment milestone
Rockley Photonics (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced that it plans to report its first quarter 2022 financial results after the market closes on Wednesday, April 27, 2022. The company also plans to host a conference call that day at 5:00 p.m. Eastern Time to review its financial results and business outlook. The conference call can be accessed by dialing 877-407-0784 from the United States or +1 201-689-8560 internationally, referencing Rockley Photonics. A live webcast and replay of the conference call can be accessed from the investor relations page on Rockley's website at investors.rockleyphotonics.com. Followi
Customer Demand Drives Early Introduction of Bioptx™ Biomarker Sensing Platform, Adding Professional Healthcare Solution to Previously Announced Consumer Wearables Solution, VitalSpex™ Rockley Ends 2021 with 17 Consumer Electronics and Medtech Contracted Customers, First Commercial Products Expected to Be Available as Early as Second Half 2022 and Volume Ramp Expected in 2023 Rockley Photonics Holdings Limited (NYSE:RKLY) ("the Company" or "Rockley"), a global leader in photonics-based health monitoring and communications solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2021. "Throughout 2021, we made tremendous progress in product
Rockley Photonics (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced that it plans to report its fourth quarter and full year 2021 financial results after the market closes on Tuesday, March 8, 2022. The company also plans to host a conference call that day at 5:00 p.m. Eastern Time to review its financial results and business outlook. The conference call can be accessed by dialing 877-407-0784 from the United States or +1 201-689-8560 internationally, referencing Rockley Photonics. A live webcast and replay of the conference call can be accessed from the investor relations page on Rockley's website at investors.rockleyphotonics.
Revenue of $1.8 million and backlog1 of $23.0 million Broadened and accelerated commercial opportunities for VitalSpex™, Rockley's end-to-end non-invasive biomarker sensing platform, by signing multiple partnerships across key markets, including tier-1 consumer electronics manufacturers, global medtech companies, and leading healthcare research institutions Rockley Photonics Holdings Limited (NYSE:RKLY) ("the Company" or "Rockley"), a global leader in photonics-based health monitoring and communications solutions, today announced its financial results for the third quarter ended September 30, 2021. "I'm very excited about our progress in the third quarter as our product development and c
Meier to focus on driving cash-efficient performance and enabling commercial production ramp Rockley Photonics Holdings Limited (NYSE:RKLY) ("Rockley"), a global leader in photonics-based health monitoring and communications solutions, today announced the appointment of Richard A. "Randy" Meier as president and chief financial officer (CFO), effective immediately. Meier will shape Rockley's financial and commercialization strategies, and lead its finance, supply chain, quality, regulatory and compliance functions. An accomplished finance and operations leader with a rich background in healthcare therapeutics and medical devices, Meier joins Rockley from Intersect ENT, a leading global ear
Rockley Photonics (NYSE:RKLY), a global leader in photonics-based health monitoring and communications solutions, today announced that it named Nicolaus Henke to its board of directors. Dr. Henke will join the board as an independent director, effective February 16, 2022, and will serve on the Nominating & Corporate Governance Committee. "I am very pleased with the appointment of Nicolaus Henke to our board. He brings a wealth of practical experience which will have an immediate impact on Rockley," said Dr. Andrew Rickman, chairman and chief executive officer of Rockley Photonics. "Throughout his career, Nico has advised top teams in leading health systems, medical device companies and pha
Julien Mininberg, Jaymin Patel and Pamela Puryear, Ph.D., Bring Significant Technology, Distribution, Consumer Brand and Human Resources Expertise Food solutions company SpartanNash (the "Company") (NASDAQ:SPTN) today announced that, following a comprehensive board refreshment process, three new independent directors, Julien Mininberg, Jaymin Patel and Pamela Puryear, Ph.D., have been appointed to the Company's Board of Directors (the "Board"), effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220207005303/en/Julien Mininberg (Photo: Business Wire) "Since last summer, our Board has undertaken a deliberate and